For these DCTs, GSK selected Medable’s end-to-end DCT platform that provides several digital capabilities including TeleVisit, eConsent, and eCOA.
The platform also provides the flexibility to implement advanced, patient-centric trials.
Under the enterprise contract with GSK, Medable will expedite the delivery of new therapies and aid in making the company’s trials more inclusive and representative of all patient populations.
Following a thorough assessment of top clinical trial platforms, Medable’s technology was selected because it best supports the goals of GSK for boosting access to research, diversity, and making trial designs that are more patient centred.
Over 300 decentralised and hybrid trials in 60 countries have deployed the software-as-a-service platform of Medable to serve more than a million patients and research subjects across the globe.
The company’s customers have attained good results with decentralised and hybrid trials, including 200% quicker subject enrolment and 50% lower expenses.
Medable co-founder and CEO Dr Michelle Longmire said: “It is an honour to be selected by GSK as its preferred partner for decentralised clinical trials.
“GSK has been a leader in innovative science for decades and is taking yet another transformational step forward by leveraging a modern, patient-centric model to conduct clinical trials with Medable.
“It’s incredibly exciting, and we are looking forward to helping millions of patients together.”
In February this year, the company introduced the Medable Partner Network, merging a varied ecosystem of technology, service, data, sites, and direct-to-patient partners that collaborate to accelerate the deployment of DCTs.